Table 2.
Performance characteristics of M371 and serum markers for detecting relapses in CSI GCTs.
| Clinically confirmed relapses | Relapse-free cases | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sensitivity | Specificity | PPV | NPV | |||||||||||
| Marker | Eligible (n) | TP | FN | (%) | 95% CI (%) | Eligible (n) | TN | FP | (%) | 95% CI (%) | (%) | 95% CI (%) | (%) | 95% CI (%) |
| bHCG | 31 | 11 | 20 | 35.5 | 19.2–54.6 | 196 | 192 | 4 | 98.0 | 94.9–99.4 | 73.3 | 51.0–95.7 | 90.6 | 86.6–94.5 |
| AFP | 32 | 8 | 24 | 25.0 | 11.5–43.4 | 196 | 184 | 12 | 93.9 | 89.5–96.8 | 40.0 | 18.5–61.5 | 88.5 | 84.1–92.8 |
| bHCG/AFP | 31 | 14 | 17 | 45.2 | 27.3–64.0 | 196 | 180 | 16 | 91.8 | 87.1–95.3 | 46.7 | 28.8–64.5 | 91.4 | 87.4–95.3 |
| M371 of all GCT | 39 | 39 | 0 | 100 | 100–100 | 219 | 211 | 8 | 96.3 | 93.9 –98.8 | 83.0 | 72.2–93.7 | 100 | 100–100 |
| M371 S | 17 | 17 | 0 | 100 | 100–100 | 172 | 166 | 6 | 96.5 | 93.8–99.3 | 73.9 | 56.9–91.8 | 100 | 100–100 |
| M371 NS | 22 | 22 | 0 | 100 | 100–100 | 47 | 45 | 2 | 95.7 | 92.9–100.0 | 91.7 | 80.7–100.0 | 100 | 100–100 |
Abbreviations: TP, true positive; FN, false negative; TN, true negative; FP, false positive; bHCG/AFP, cases with either elevation of bHCG or AFP or both; S, seminoma; NS, nonseminoma.